These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 29669169)

  • 21. The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024).
    Kleiblová P; Novotný J; Cibula D; Curtisová V; Dubová O; Foretová L; Germanová A; Janatová M; Havránek O; Hojsáková M; Hudcová M; Koudová M; Krutílková V; Palacova M; Paulich S; Petrakova K; Presl J; Puchmajerová A; Soukupová J; Šenkeříková M; Šimková Z; Štěpánková H; Šubrt I; Tachecí I; Tesner P; Urban O; Veselá K; Vilímová Š; Vlčková Z; Vočka M; Weinberger V; Zikán M; Zimovjanová M; Kleibl Z
    Klin Onkol; 2024; 38(4):292-299. PubMed ID: 39174333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.
    Joris S; Denys H; Collignon J; Rasschaert M; T'Kint de Roodenbeke D; Duhoux FP; Canon JL; Tejpar S; Mebis J; Decoster L; Aftimos P; De Grève J
    ESMO Open; 2023 Dec; 8(6):102041. PubMed ID: 37852034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hereditary genes and SNPs associated with breast cancer.
    Mahdi KM; Nassiri MR; Nasiri K
    Asian Pac J Cancer Prev; 2013; 14(6):3403-9. PubMed ID: 23886119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry.
    Scott CM; Joo JE; O'Callaghan N; Buchanan DD; Clendenning M; Giles GG; Hopper JL; Wong EM; Southey MC
    PLoS One; 2016; 11(11):e0165436. PubMed ID: 27902704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.
    Pennington KP; Walsh T; Lee M; Pennil C; Novetsky AP; Agnew KJ; Thornton A; Garcia R; Mutch D; King MC; Goodfellow P; Swisher EM
    Cancer; 2013 Jan; 119(2):332-8. PubMed ID: 22811390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germline and Somatic Mutations in Prostate Cancer for the Clinician.
    Cheng HH; Sokolova AO; Schaeffer EM; Small EJ; Higano CS
    J Natl Compr Canc Netw; 2019 May; 17(5):515-521. PubMed ID: 31085765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
    Giri VN; Hegarty SE; Hyatt C; O'Leary E; Garcia J; Knudsen KE; Kelly WK; Gomella LG
    Prostate; 2019 Mar; 79(4):333-339. PubMed ID: 30450585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing.
    Giri VN; Hartman R; Pritzlaff M; Horton C; Keith SW
    JCO Precis Oncol; 2022 May; 6(1):e2200234. PubMed ID: 35666082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
    Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
    Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications.
    Brandão A; Paulo P; Teixeira MR
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repair-Gene Mutations Uncovered in Metastatic Prostate Cancer.
    Cancer Discov; 2016 Sep; 6(9):OF3. PubMed ID: 27460689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate Cancer Germline Variations and Implications for Screening and Treatment.
    Dias A; Kote-Jarai Z; Mikropoulos C; Eeles R
    Cold Spring Harb Perspect Med; 2018 Sep; 8(9):. PubMed ID: 29101112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germline genetics of prostate cancer.
    Khan HM; Cheng HH
    Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S3-S12. PubMed ID: 35657157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
    Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
    Giri VN; Knudsen KE; Kelly WK; Cheng HH; Cooney KA; Cookson MS; Dahut W; Weissman S; Soule HR; Petrylak DP; Dicker AP; AlDubayan SH; Toland AE; Pritchard CC; Pettaway CA; Daly MB; Mohler JL; Parsons JK; Carroll PR; Pilarski R; Blanco A; Woodson A; Rahm A; Taplin ME; Polascik TJ; Helfand BT; Hyatt C; Morgans AK; Feng F; Mullane M; Powers J; Concepcion R; Lin DW; Wender R; Mark JR; Costello A; Burnett AL; Sartor O; Isaacs WB; Xu J; Weitzel J; Andriole GL; Beltran H; Briganti A; Byrne L; Calvaresi A; Chandrasekar T; Chen DYT; Den RB; Dobi A; Crawford ED; Eastham J; Eggener S; Freedman ML; Garnick M; Gomella PT; Handley N; Hurwitz MD; Izes J; Karnes RJ; Lallas C; Languino L; Loeb S; Lopez AM; Loughlin KR; Lu-Yao G; Malkowicz SB; Mann M; Mille P; Miner MM; Morgan T; Moreno J; Mucci L; Myers RE; Nielsen SM; O'Neil B; Pinover W; Pinto P; Poage W; Raj GV; Rebbeck TR; Ryan C; Sandler H; Schiewer M; Scott EMD; Szymaniak B; Tester W; Trabulsi EJ; Vapiwala N; Yu EY; Zeigler-Johnson C; Gomella LG
    J Clin Oncol; 2020 Aug; 38(24):2798-2811. PubMed ID: 32516092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia.
    Krivokuca A; Boljevic I; Jovandic S; Magic Z; Mandic A; Tomasevic Z; Brankovic-Magic M
    J Hum Genet; 2019 Apr; 64(4):281-290. PubMed ID: 30651582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.
    Maia S; Cardoso M; Paulo P; Pinheiro M; Pinto P; Santos C; Pinto C; Peixoto A; Henrique R; Teixeira MR
    Fam Cancer; 2016 Jan; 15(1):111-21. PubMed ID: 26289772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.